Yan Leyfman Highlights mRNA Multi-Target CAR T Triumphs in Glioblastoma Models
Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn about an article by Oula K. Dagher et al. published on Cell Press:
“Turning the Tide Against Glioblastoma.
CAR T cells have crushed blood cancers with remissions lasting a decade… but solid tumors like GBM remain a fortress.
The Innovation
This study unveils a 3-pronged attack:
– mRNA-based CAR T cells (delivered via electroporation or LNPs) – high efficiency, but transient expression
– Multi-targeting GBM receptors – no single point of escape
– Maximal surgical resection – reducing tumor burden before cell therapy
Key Findings
– Potent in vitro tumor killing
– Defined a therapeutic window for optimal timing
– In GBM mouse models, combining surgery + locoregional multivalent CAR T cells (MVCAR) → durable complete remissions.
– 5-day expanded T cells outperformed quiescent ones
– MVCAR > pooled CAR T (CARPool) in orthotopic resection models
Why It Matters
A readily translatable platform that could finally give CAR T cells a foothold in the solid tumor battlefield.”
Title: Preclinical Efficacy of Multi-targeting mRNA-based CAR T Cell Therapy in Resection Models of Glioblastoma
Authors: Oula K. Dagher, Martin Pedard, Darel Martinez Bedoya, Shawna K. Brookens, Denis Migliorini, Avery D. Posey Jr.
More posts featuring Yan Leyfman on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023